<h2>What the AAP recommends
The American Academy of Pediatrics has released its COVID-19 vaccine recommendations for the 2026–2027 season. Infants and children 6 through 23 months of age are recommended to receive the 2026–2027 COVID-19 vaccine if they have no contraindications. This age group carries a hospitalization and mortality burden that can rival or exceed that of adults in their 60s and 70s.
For children and adolescents 2 through 18 years, the AAP recommends a single dose for those at increased risk of severe COVID-19 (including moderate or severe immunocompromise, certain medical conditions, residents of congregate settings, never-vaccinated children, and those living with a high-risk household contact). Children not in those risk groups may be offered a single dose if a parent or guardian desires protection.
Background
COVID-19 continues to circulate seasonally. Updated formulations have shown reduced emergency and urgent-care visits in recent seasons. Myocarditis rates associated with newer mRNA formulations have declined compared with earlier versions. The AAP has taken a leading role in pediatric immunization guidance while federal advisory processes have been in flux.
Competing viewpoints
Some families and clinicians prefer a risk-based approach for older children and emphasize parental choice. Others point to the still-elevated risk in the youngest children and to household protection as reasons for broader uptake. The AAP’s own language distinguishes the universal recommendation for 6–23 months from the risk-based or parent-request approach for older ages.
What parents can do
- Talk with your child’s clinician about whether a 2026–2027 dose is recommended or optional for your child’s age and health status.
- Ask about timing relative to other seasonal vaccines (influenza, RSV) and any recent COVID-19 infection.
- Review the AAP immunization schedule and dosing guide for details on series completion for the youngest children.
What to watch next
Watch uptake rates among the 6–23-month age group, any further updates to product availability or dosing, and how real-world effectiveness data for the 2026–2027 formulations look by mid-season. Also watch whether household or community transmission patterns change the risk calculus for older children.
This is educational information only, not medical advice. Decisions about vaccination should be made with a qualified clinician who knows the child’s history.</h2>
Comments (0)
No comments yet.
Sign in to comment.